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Introduction: Transcriptional coactivator with PDZ-binding motif 
(TAZ) is known to bind to a variety of transcription factors to con-
trol cell differentiation and organ development. Recently, TAZ has 
been identified as an oncogene and has an important role in tumori-
genicity of non-small cell lung cancer (NSCLC). Therefore, TAZ 
may present a novel target for the future diagnosis, prognosis, and 
therapy for lung cancer. We investigated the relationship between 
TAZ expression and clinicopathological parameters and determined 
its prognostic significance concerning survival in patients with 
resected NSCLC.
Methods: TAZ expression was immunohistochemically studied in 
181 consecutive patients with NSCLC and 20 cases of normal lung 
tissue. The association between expression of TAZ and clinicopatho-
logical parameters was evaluated. Kaplan-Meier survival analysis 
and Cox proportional hazards models were used to estimate the effect 
of TAZ expression on survival.
Results: TAZ expression was observed in 121 of the 181 
(66.8%) NSCLC. TAZ had nuclear and cytoplasmic expres-
sion. Clinicopathologically, TAZ expression was significantly 
associated with lung adenocarcinoma (p 5 0. 002), poorer dif-
ferentiation (p 5 0.001), p-tumor, node, metastasis stage (p 5 
0.001), lymph node metastasis (p 5 0.032), intratumoral vascu-
lar invasion (p 5 0.004), pleural invasion (p 5 0.003), adjuvant 
chemotherapy (p 5 0.044), and poorer prognosis (p 5 0.002). 
Multivariable analysis confirmed that TAZ expression increased 
the hazard of death after adjusting for other clinicopathological 
factors (hazard ratio, 2.56; 95% confidence interval, 1.39–4.66; 
p 5 0.01). overall survival was significantly prolonged in TAZ 
negative group when compared with TAZ positive group (61.8 
versus 47.1 months; p  0.0001), as was disease-free survival 
(44.3 versus 25.1 months; p  0.0001). Adjuvant chemotherapy 
prolonged overall survival among resected NSCLC patients with 
TAZ positive expression (p 5 0.001).
Conclusions: This study suggests that TAZ expression is a prognos-
tic indicator of poorer survival probability for patients with resected 
NSCLC.
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Primary lung cancer is the leading cause of cancer mor-tality worldwide. Although surgical resection is the 
optimal treatment of early-stage, non-small cell lung can-
cer (NSCLC), 5-year survival rates for surgically resect-
able NSCLC are still unsatisfactory and range from 19% for 
stage IIIA to 63% for stage IA.1 Recurrence that accounts 
for mortality occurs most commonly in distant extrathoracic 
regions. Recently, adjuvant cisplatin-based chemotherapy has 
been recommended to improve survival for NSCLC patients 
with completely resected stage II and stage IIIA.2 Although 
adjuvant chemotherapy shows some improvement of 5-year 
overall survival (oS), which ranges from 4 to 15%, adjuvant 
chemotherapy is also associated with serious adverse side 
effects. Moreover, the benefit of platinum-based adjuvant 
chemotherapy for stage IB patients has not been established.3 
Therefore, the identification of predictive and/or prognostic 
markers is important to stratify patients with resected NSCLC 
and select high-risk patients who should receive aggressive 
adjuvant chemotherapy.
Transcriptional coactivator with PDZ-binding motif 
(TAZ), also called WW-domain containing transcription 
regulator 1 (WWTR1), is a WW-domain-containing tran-
scriptional coactivator that activates many transcriptional 
factors, which have important roles in the development 
of various tissue in mammals.4 TAZ has also been shown 
to regulate stem cell differentiation and renewal through 
modulation of the transcription factors PPARg, Runx2, and 
Smad.5 Recently, TAZ has been identified as a component 
of an emerging Hippo-LATS tumor suppressor pathway that 
has important roles in regulating cell proliferation, apopto-
sis, tumor formation, and organ size in both Drosophila and 
mammals.6 Significantly, human homologs of Drosophila 
Hippo and LATS tumor suppressors, MstII and LATS1/2, 
can suppress tumor cell growth by phosphorylating and 
inhibiting TAZ and its protein highly paralog Yes-associated 
protein (YAP).7 Zhou et al.8 showed for the first time that 
TAZ is an oncogene in NSCLC. TAZ was overexpressed 
in NSCLC cells. To our knowledge, no report has been 
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published concerning the relationships between TAZ expres-
sion and clinicopathological features and prognosis of lung 
cancer patients. Therefore, the objectives of this study were 
(1) to immunohistochemically examine TAZ expression in 
tumor samples of 181 NSCLC patients, (2) to evaluate the 
relationships between TAZ expression and the clinicopatho-
logical parameters of NSCLC, and (3) to estimate the prog-
nostic impact of TAZ on survival in patients with resected 
NSCLC patients.
PATIENTS AND METHODS
Patient Selection and Tissue Sample Collection
A total of 181 consecutive NSCLC patients who under-
went complete resection (lobectomy and mediastinal lymph 
node dissection with microscopic examination of margins 
showing no tumor cells) from January 2003 to March 2005 at 
the First Affiliated Hospital of Guangzhou Medical University 
were included in this retrospective cohort study.
Patients who have previous malignant disease, second 
primary tumor, or those who received preoperative radio-
therapy and/or chemotherapy were excluded. Twenty cases 
of normal lung tissue were included in this study. Three 
micrometer-thick sections were stained with hematoxylin and 
eosin. The histological diagnosis was based on the criteria 
of the World Health organization/International Association 
for the Study of Lung Cancer (WHo/IASLC) classification 
of lung and pleural tumors.9 Each case was reassigned for 
tumor, node, metastasis (TNM) classification and pathologi-
cal stage on the basis of the new IASLC staging system.10 
The following clinical and pathologic parameters were ret-
rospectively reviewed and analyzed for each case: age at 
surgical resection, gender, smoking habits, histological type, 
tumor differentiation, pathological TNM (p-TNM) stage, 
nodal status, intratumoral vascular invasion, pleural invasion, 
receiving adjuvant chemotherapy, oS, and progression-free 
survival time (PFS) after surgery. The study was approved 
by the Ethics Committee of Sun Yat-Sen University cancer 
center. Informed consent was obtained from all patients for 
specimen collection.
Immunohistochemical Staining for TAZ
After dewaxing in xylene and rehydrating stepwise 
in ethanol, sections were subjected to heat-induced antigen 
retrieval. Endogenous peroxidase activity and nonspecific 
binding were blocked with 3% H
2
o
2
 and nonimmune sera, 
respectively. Sections were then incubated with primary anti-
bodies overnight at 4C. The primary antibodies were used in 
this study: rabbit polyclonal TAZ (H-70) antibody (sc-48805, 
1:200, Santa Cruz). The following day, primary antibody was 
detected using the appropriate labeled Streptavidin-Biotin kit 
(Maixin Biotechnology, Fuzhou, China) according to the man-
ufacturer’s instructions. Immunolabeled sections were visu-
alized with 3,3´-diaminobenzidine and counterstained with 
hematoxylin. Sections were counterstained with hematoxylin, 
dehydrated, and mounted. Sections were stained in parallel 
without primary antibody to provide a negative control.
Evaluation of Immunohistochemical Staining
Two investigators (J.H.H. and S.X.L.) separately evalu-
ated all the specimens in a blinded manner. Variant cases were 
reviewed and discussed until a consensus was obtained. Five 
areas were selected at random and scored. The percentage of 
tumor cells with positive staining of TAZ was determined at 
high magnification (3200). For TAZ, nuclear and cytoplasmic 
immunostaining in tumor cells was considered to be positive. 
Tissue was scored (H score) based on the total percentage of 
positive cells and the intensity of the staining (11, 21, or 
31), where H 5 (% 11 31) 1 (% 21 32) 1 (% 31 33). 
The sample was considered negative if H 5 0 and positive if 
H was more than 0; positive samples were also categorized as 
weak if H 5 1 to 50 and strong if H was more than 50. A mini-
mum of 100 cells were evaluated in calculating the H score.11
Cell Lines
The cell lines included seven adenocarcinoma (AD) 
(A549, NCI-H1975, NCI-H358, PC9, NCI-H3255, NCI-
H1838, and HCC827), two squamous cell carcinoma (SCCs) 
(NCI-H2170 and SK-MES-1), one NSCLC line derived from 
metastatic lymph node (NCI-H1299), one mucoepidermoid 
pulmonary carcinoma (NCI-H292), and three normal bronchial 
epithelial cell lines (HBE-135, HBE-154 and BEAS-2B). PC9, 
NCI-H1975, A549 cell lines were obtained from Pro. Wu YL 
(Guangdong Provincial General Hospital, China). BEAS-2B, 
HBE-135, and HBE-135 cell lines were obtained from Dr. 
Yang ZF (State Key laboratory of Respiratory Disease, China). 
NCI-H2170, SK-MES-1, NCI-H292, NCI-H1299, NCI-H358, 
NCI-3255, NCI-1838, and HCC827 were purchased from the 
American Type Culture Collection (Manassas, VA). These cell 
lines were routinely cultured in RPMI-1640 supplemented with 
10% fetal calf serum at 37C in a 5% Co
2
 atmosphere.
Western Blot
Total protein was isolated from cells using Cell 
Extraction Buffer (Biosource, Camarillo, CA) supplemented 
with protease and phosphatase inhibitors and precleared using 
centrifugation, followed by measuring protein concentrations 
using the BCA Protein Assay kit (Pierce, Rockford, IL). Rabbit 
polyclonal TAZ antibody (sc-48805, Santa Cruz) and  b-actin 
(4967, Cell Signaling Technology) antibodies were used as 
primary antibodies. Equal protein loading was confirmed with 
probing for b-actin expression. The blots were washed and 
incubated with horseradish peroxidase-conjugated goat anti-
rabbit antibody (Calbiochem, La Jolla, CA). Proteins were 
visualized by Amersham enhanced chemiluminescence (GE 
Healthcare, Palo Alto, CA).
Statistical Analysis
Correlation between immunohistochemical expression 
and clinicopathological parameters was analyzed by  x2 test. 
Survival curves were assessed by the Kaplan-Meier method 
and compared by the log-rank test. Multivariate survival 
analysis was performed on all parameters, which were found 
to be significant on univariate analysis using the Cox regres-
sion model. Two-sided p  0.05 was considered statistically 
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significant. All analyses were performed with the SPSS 16.0 
software package.
RESULTS
Patient Characteristics
The baseline characteristics of the patients are shown 
in Table 1. A total of 117 men and 64 women were included 
with ages ranging from 30 to 78 years (median, 57 years) 
of which 113 (62.4%) were former smokers. There were 
56 (31.0%) stage I (14 stage IA and 42 stage IB), 63 
(34.8%) stage II (23 stage IIA and 40 stage IIB), and 62 
(34.2%) stage IIIA diseases, including 114 (63.0%) ADs, 
61 (33.7%) SCCs, four (2.2%) large cell carcinomas, and 
six (1.1%) adenosquamous carcinoma. one hundred twen-
ty-seven patients received three to six cycles of tri-weekly 
adjuvant chemotherapy, of whom 150 (83.0%) finished four 
cycles. The adjuvant chemotherapy regimens included doc-
etaxel (19.0%), gemcitabine (21.3%), paclitaxel (36.2%), 
and vinorelbine (23.5%) combined with cisplatin or 
carboplatin.
TAZ Expression in NSCLC
First, we examined the expression in 14 lung cell 
lines by Western blot using a polyclonal antibody raised 
against TAZ. Specifically, no TAZ expression was 
observed in three nontumorigenic human bronchial epi-
thelial cell lines, whereas overexpression of TAZ was 
observed in seven of 11 (63.6%) tumorigenic NSCLC cell 
lines (Figure 1).
Subsequently, we investigated TAZ expression in 181 
cases of NSCLC tissue and 20 cases of normal lung tissue 
by immunohistochemistry. The TAZ protein was mainly 
accumulated in the nucleus with a less cytoplasmic pres-
ence (Figure 2). TAZ positive expression in tumor cells was 
observed in 121 of 181 (66.8%) NSCLC (Table 1). They 
were further divided into 85 of 114 (74.6%) ADs, 36 of 61 
(59.0%) SCCs. None of large cell carcinomas expressed 
TABLE 1. Relationships between TAZ Expression and Clinicopathological parameters (n 5 181)
Characteristics
TAZ Expression (n, %)
Total p
Weak  
Positive (n 5 76)
Strong  
Positive (n 5 45)
Negative  
(n 5 60)
Age (yr)
 65 46 (45.5) 23 (22.8) 32 (31.7) 101 0.539
 65 30 (37.5) 22 (27.5) 28 (35) 80  
Gender
 Male 47 (40.2) 28 (23.9) 42 (25.9) 117 0.568
 Female 29 (45.3) 17 (26.6) 18 (28.1) 64  
Smoking history
 Former smoker 51 (45.1) 28 (24.8) 34 (30.1) 113 0.459
 Never smoker 5 (36.8) 17 (25.0) 26 (38.2) 68
Histology
 Adenocarcinoma 55 (48.3) 30 (26.3) 29 (25.4) 114 0.002
 Squamous carcinoma 21 (34.4) 15 (24.6) 25 (41.0) 61  
 others 0 0 6 (100) 6
Tumor differentiation
 Well/moderately 38 (33.6) 22 (19.5) 53 (46.9) 113 0.001
 Poorly 38 (55.9) 23 (33.8) 7 (10.3) 68  
p-TNM stage
 StageI 17 (30.4) 7 (12.5) 32 (57.1) 56 0.001
 Stage II/III 59 (47.2) 38 (30.4) 28 (22.4) 125  
Nodal status
 N0 22 (37.3) 10 (16.9) 27 (45.8) 59 0.032
 N1/N2/N3  54 (44.3) 35 (28.7) 33 (27.0) 122
Vascular invasion
 Yes 25 (38.5) 25 (38.5) 15 (23.0) 65 0.004
 No 51 (44.0) 20 (17.2) 45 (38.8) 116  
Pleural invasion
 Yes 15 (34.9) 19 (44.2) 9 (20.9) 43 0.003
 No 61 (44.2) 26 (18.8) 51 (37.0) 138  
Adjuvant chemotherapy
 Yes 59 (46.5) 33 (26.0) 35 (27.5) 127 0.044
 No  17 (31.5) 12 (22.2) 25 (46.3) 54
p-TNM, pathological TNM.
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TAZ. TAZ overexpression was not detected in non-neoplas-
tic bronchial or alveolar epithelial cells.
Relationship between TAZ Expression and 
Clinicopathological Characteristics
The relationships between TAZ expression and clini-
copathologic characteristics are summarized in Table 1. TAZ 
positive expression was more frequently detected in ADs than 
in SCCs and other histological subtypes (p 5 0.002). TAZ 
positive expression was also related to poorer differentiation 
(p 5 0.001), p-TNM stage (p 5 0.001), lymph node metastasis 
(p 5 0.032), intratumoral vascular invasion (p 5 0.004), pleural 
invasion (p 5 0.003), and adjuvant chemotherapy (p 5 0.044); 
FIGURE 1. Western blot analysis of TAZ expres-
sion in normal human bronchial epithelial (HBE) 
and NSCLC cell lines. Cell lysates extracted from 
these cell lines were subjected to Western blot 
using anti-TAZ and anti-b-actin antibodies. The 
levels of b-actin were used as internal protein  
loading controls.
FIGURE 2. Immunohistochemistry staining of TAZ in NSCLC. TAZ positive expression in both nucleus and cytoplasm of lung 
adenocarcinoma (A). TAZ positive expression in lung squamous carcinoma, staining in both cytoplasm and nucleus of tumor 
cells (B). Negative TAZ expression in lung adenocarcinoma (C). Negative expression in normal lung tissue (D). Original magnifi-
cation, 3200.
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whereas there was no significant association between TAZ 
expression and age, gender, smoking history.
Effect of TAZ Expression on Survival with 
Univariable and Multivariable Analysis
To find practically useful prognostic factors, we per-
formed univariate analysis for TAZ expression and nine 
clinicopathological factors (Table 2). The clinicopathologi-
cal factors included age, gender, smoking history, histology, 
p-TNM stage, adjuvant chemotherapy, tumor differentiation, 
vascular invasion, and pleural invasion. TAZ positive expres-
sion, p-TNM stage, adjuvant chemotherapy, and tumor dif-
ferentiation were four significant prognostic factors (TAZ 
positive expression: p 5 0.002, p-TNM stage: p  0.0001, 
adjuvant chemotherapy: p  0.0001, tumor differentiation: 
p  0.0001). The crude hazard ratio (HR) of TAZ positive 
compared with TAZ negative was 3.26 (95% confidence inter-
val [CI], 2.43–5.51), which indicate that TAZ positive status 
increased the hazard of lung cancer-related death by three 
times that of TAZ negative.
We then performed multivariate analysis for these four 
factors whose presence significantly affected prognosis and 
for demographic factors, such as age and sex. The results 
showed that TAZ positive expression, p-TNM stage, and 
adjuvant chemotherapy were significantly related to progno-
sis (TAZ positive expression: p 5 0.006, p-TNM stage: p 5 
0.003, adjuvant chemotherapy: p 5 0.001). After controlling 
for the effects of the above clinicopathological factors, the 
adjusted HR of TAZ positive expression became 2.54 (95% 
CI, 1.30–4.94; p 5 0.006) in comparison with TAZ negative 
expression (Table 3).
We also performed an analysis by using propensity score 
to adjust the effect of TAZ expression by transforming all 
other confounding variables (including age, gender, smoking 
history, histology, p-TNM stage, and adjuvant chemotherapy) 
into a single estimator and revealed that after the adjustment, 
the HR of TAZ expression became 2.56 (95% CI, 1.39–4.66; 
p 5 0.01). These findings suggested that TAZ positive was an 
independent and significant predictor of poorer survival.
Kaplan-Meier Estimate of Survival for Resected 
NSCLC Patients with or without TAZ Expression
All the patients were included in the survival analysis. 
The overall follow-up durations ranged from 8 to 73 months 
(median, 62.1 months). Five-year cumulative survival prob-
ability was 20.7% for the TAZ positive group and 43.3% for 
the TAZ negative group. The median oS was 47.1 months for 
patients with TAZ positive expression, 61.8 months for patients 
with TAZ negative expression, indicating a significantly poorer 
rate of oS in the TAZ positive group compared with that in 
the TAZ-negative group (p  0.0001, Figure 3A). In further 
analyses, TAZ positive expression was significantly associated 
with shorter oS for stage II/III patients (p  0.0001, Figure 
3C) and for stage I patients (p 5 0.023, Figure 3B). Five-year 
survival probability was 12.0% for TAZ positive versus 27.3% 
for TAZ negative patients with stage II/III, and 48.3% for TAZ 
positive versus 63.0% for TAZ negative patients with stage 
I. Similarily, TAZ positive patients had significantly shorter 
PFS (25.1 months) than TAZ negative patients (44.3 months) 
in the entire population (p  0.0001) (Figure 4A). There were 
also significant differences of PFS between TAZ positive 
patients and TAZ negative patients among stage I (p 5 0.017) 
and stage II/III (p  0.0001) postoperative patients (Figure 
4B–C). Median PFS was longer in TAZ weak positive patients 
(28.6 months) than in patients with TAZ strong positive 
patients (21.6 months) (p 5 0.044) (Figure 5A). In contrast, 
there were no significant difference of median oS between 
those with weak positive (48.1 months) and strong positive 
expression (44.7 months) (p 5 0.495) (Figure 5B).
TABLE 2. Univariable Analysis for the Effect of TAZ 
Expression on Overall Survival (n 5 181)
Factors
Univariable Analysis
HR 95% CI p
TAZ expression
 Positive vs. negative 3.26 2.43–5.51 0.002
Age (yr)
 65 vs. 65 1.23 0.58–1.92 0.081
Gender
 Male vs. female 1.86 0.85–2.88 0.076
Smoking history    
 Smoker vs. none smoker 1.92 0.89–3.15 0.062
Histology
 AD vs. non-AD 1.36 0.75–2.27 0.056
p-TNM stage
 Stage II/III vs. stage I 3.83 2.12–6.86 0.0001
Adjuvant chemotherapy
 No vs. yes 4.12 2.80–7.16 0.0001
Tumor differentiation
 Poorly vs. well/moderately 3.91 2.23–7.13 0.0001
Vascular invasion
 Yes vs. no 1.15 0.69–2.83 0.071
Pleural invasion
 Yes vs. no 1.54 0.78–2.46 0.094
AD, adenocarcinoma; p-TNM, pathological TNM; HR, hazard ratio; CI, confidence 
interval.
TABLE 3. Multivariable Analysis for the Effect of TAZ 
Expression on Overall Survival (n 5 181)
Factors
Multivariable Analysis
HR 95% CI p
TAZ expression
 Positive vs. negative 2.54 1.30–4.94 0.006
Age (yr)
 65 vs. 65 1.14 0.77–1.96 0.881
Tumor differentiation
 Poorly vs. well/moderately 1.72 0.63–2.15 0.348
p-TNM stage
 Stage II/III vs. stage I 2.83 1.63–4.86 0.003
Adjuvant chemotherapy
 No vs. yes 2.13 1.79–3.90 0.001
HR, hazard ratio; CI, confidence interval; TAZ, transcriptional coactivator with 
PDZ-binding motif; p-TNM, pathological TNM.
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FIGURE 3. Overall survival curves with TAZ expression 
results in the entire population (A), in stage I NSCLC patients 
(B), and in stage II/ III NSCLC patients (C).
FIGURE 4. Disease-free survival curves with TAZ expression 
results in the entire population (A), in stage I NSCLC patients 
(B), and in stage II/ III NSCLC patients (C).
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Next, we compared oS between adjuvant chemotherapy 
group and observation group among patients with TAZ posi-
tive expression or those without TAZ expression. In NSCLC 
patients with TAZ positive expression, the median oS in 
patients with adjuvant chemotherapy was significantly pro-
longed, at 52.8 months when compared with 42.4 months in 
the observation group (HR, 0.81; 95% CI, 0.72–0.89; p 5 
0.001) (Figure 6A). In patients with TAZ negative expression, 
the median oS was 61.8 months for those without adjuvant 
chemotherapy and 61.7 months for those received adjuvant 
chemotherapy (HR, 0.93; 95% CI, 0.78–1.11; p 5 0.698) 
(Figure 6B). Subgroup analysis indicated that the survival 
benefit of receiving adjuvant chemotherapy was only shown in 
the TAZ positive subgroup.
DISCUSSION
In this study, we demonstrate for the first time that TAZ 
expression is associated with poorer prognosis and is an inde-
pendent prognostic factor for survival in patients with resected 
NSCLC patients. TAZ positive expression was significantly 
associated with decreased oS and disease-free survival prob-
ability among stage II/III and stage I patients, especially stage 
II/III subgroup (p  0.0001). Although TAZ was detected in 
both well/moderately and poorly differentiated tumors, its 
expression incidence was significantly higher in poorly dif-
ferentiated ones (p 5 0.001). Moreover, in agreement with 
previous reports of papillary thyroid carcinoma,12 our findings 
revealed that TAZ expression was significantly associated with 
intratumoral vascular invasion, pleural invasion, and nodal 
status in NSCLC. These results suggest that TAZ expression 
may be important for the acquisition of migration and inva-
sion capabilities of tumor cells, which subsequently results in 
poorer prognosis in patients with resected NSCLC.
Zhou et al.8 found that TAZ was relatively low in all 
normal (HBE154 and HBE158) and immortalized HBE cell 
lines (HBE135, BEAS-2B, and NL20) but was overexpressed 
FIGURE 6. Kaplan-Meier estimates of overall survival 
between adjuvant chemotherapy group and observation 
group among patients with TAZ positive expression (A) or 
those without TAZ expression (B).
FIGURE 5. Disease-free survival curve (A) and overall sur-
vival (B) among patients with TAZ positive expression.
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in nine of 11 (81%) tumorigenic NSCLC cell lines examined. 
However, in our study, TAZ expression was not observed in 
mature bronchial or alveolar epithelial cells of non-neoplastic 
peripheral lung tissues but was only detected in tumor cells. 
de Cristofaro et al.12 reported that the increase of TAZ expres-
sion is a marker of papillary thyroid carcinoma. Particularly, 
the immunohistochemical staining observed in the cytoplasm 
suggests that a dislocation of TAZ might be one of the causes 
of the malignant phenotype. In our study, TAZ was expressed 
in 66.8% NSCLC, most of which were located in the nuclei 
and cytoplasm of tumor cells. The location of TAZ staining in 
NSCLC is similar to that of YAP (a highly paralog of TAZ) in 
lung cancer.13
Although the molecular mechanism governing the 
function of TAZ is not fully clear, one of the mechanisms 
for TAZ action is to trigger a loss of epithelial morphol-
ogy, to promote cell migration and invasion, and to support 
anchorage-independent growth, all of which are important 
for cancer initiation, progression, and invasion.14 TAZ over-
expression is not sufficient to enable HBE135 immortalized 
human bronchial epithelial cells to grow into sizeable colo-
nies in soft agar, nevertheless, it is important for anchorage-
independent growth of HBE135 cells. Moreover, A549 lung 
cancer cells with TAZ knockdown exhibited a significant 
reduction in anchorage-independent growth on soft agar in 
vitro and tumor growth in nude mice in vivo. Together, these 
studies strongly suggest that TAZ is vital for the tumorigene-
sis of NSCLC cells.8 Given that YAP and TAZ have indepen-
dent and overlapping functions, it is possible that both YAP 
and TAZ may be involved in lung tumorigenesis in vivo.15
In our study, NSCLC patients with TAZ positive expres-
sion demonstrated a significant survival benefit from adjuvant 
chemotherapy, whereas those with TAZ negative expression 
did not. It may be speculated that because patients with TAZ 
positive expression was related to late stage NSCLC and 
may benefit more from adjuvant chemotherapy because of 
the poorer prognosis. de Cristofaro et al.12 demonstrated that 
TAZ confered a growth advantage to thyroid cells in vitro 
and induced epithelia-mesenchymal transition, which was 
associated with cancer cell invasion and metastasis. ASPP1 
(apoptosis-stimulating protein of p53) can inhibit the interac-
tion of YAP/TAZ with LATS1 (large tumor suppressor 1), a 
kinase that phosphorylates YAP/TAZ and promotes cytoplas-
mic sequestration and protein degradation.16 This function of 
ASPP1 therefore enhances nuclear accumulation of YAP/TAZ 
and YAP/TAZ-dependent transcriptional regulation. The con-
sequence of YAP/TAZ activation by ASPP1 is to inhibit apop-
tosis, in part through the down-regulation of Bim expression, 
leading to resistance to anoikis (a form of programmed cell 
death, which is induced by anchorage-dependent cells detach-
ing from the surrounding extracellular matrix) and enhanced 
cell migration. Resistance to anoikis is regarded as a prereq-
uisite for metastasis, therefore, activation of YAP/TAZ may 
contribute to lung cancer metastasis. In summary, enhanced 
expression of TAZ induces epithelia-mesenchymal transition 
and resistance of anoikis, which are the key mechanisms by 
which tumor cells gain invasive and metastatic ability. This 
may explain why higher expression of TAZ is associated with 
poor prognosis of NSCLC and the survival benefit from adju-
vant chemotherapy.
Lai et al.17 reported that elevated levels of TAZ found 
in human breast cancer cells was responsible for their resis-
tance to Taxol. DNA microarray analysis identified the onco-
genes Cyr61 and CTGF as downstream transcriptional targets 
of TAZ. Short hairpin RNA-mediated knockdown of both 
Cyr61 and CTGF reversed TAZ-induced Taxol resistance in 
breast cancer cells. Interaction of TAZ with the TEAD fam-
ily of transcription factors was essential for TAZ to activate 
the Cyr61/CTGF promoters and to induce Taxol resistance. 
Nevertheless, because of the small amount of TAZ positive 
patients in our study, we could not stratify the data according 
to the clinical TNM stage and chemotherapy regimens. Thus, 
large-scale clinical study is needed to clarify whether or not 
TAZ expression is a prognostic indicator to help select patients 
who might benefit from receiving adjuvant chemotherapy.
In conclusion, we have provided the first clinical evi-
dence that TAZ is expressed in a subset of NSCLC and its 
expression is related to clinicopathological factors. We dem-
onstrated that TAZ expression is a prognostic indicator of poor 
survival among patients with resected NSCLC, although its 
prognostic significance still requires confirmation with larger 
patient populations.
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